NCT02487355

Brief Summary

The study will conduct to compare the efficacy of Magnesium sulphate \& dexmedetomidine used as adjuvants to bupivacaine in caudal block to provide intra-operative anesthesia as well as post -operative analgesia in pediatric patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started May 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 29, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 1, 2015

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

September 26, 2017

Status Verified

September 1, 2017

Enrollment Period

2.6 years

First QC Date

June 29, 2015

Last Update Submit

September 25, 2017

Conditions

Keywords

dexmedetomidinemagnesium sulphate

Outcome Measures

Primary Outcomes (1)

  • Time to first analgesic requirement

    The time from end of surgery to the first requirement of postoperative analgesia

    24 hours

Secondary Outcomes (1)

  • Postoperative sedation scores

    24 hours

Study Arms (4)

group (MG)

ACTIVE COMPARATOR

Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine

Drug: Magnesium Sulphate

group (D)

ACTIVE COMPARATOR

Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine

Drug: Dexmedetomidine

group (MD)

ACTIVE COMPARATOR

50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine

Drug: Dexmedetomidine + Magnesium Sulphate + Bupivacaine

group (C)

ACTIVE COMPARATOR

1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline

Drug: Bupivacaine

Interventions

Dexmedetomidine 1 μg/ kg

group (D)

Magnesium Sulphate 50 mg

group (MG)

1ml/kg of 0.25%of bupivacaine

group (C)

Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine

group (MD)

Eligibility Criteria

Age6 Months - 6 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Healthy male and female children, ASA I and II,Aged 6 months to 6 years, , undergoing elective surgical procedures expected to last more than 90 min, and scheduled to receive general anesthesia combined with caudal extradural block

You may not qualify if:

  • Allergy to local anesthetics,coagulation disorders, infection at site of injection, anatomic abnormalities and congenital anomalies like spina bifid, ASA III or higher, Parental refusal and the current use of Calcium Channel Blockers or Medication that may affect the neurologic system

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut Univeristy Hospital

Asyut, 715715, Egypt

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Interventions

DexmedetomidineMagnesium SulfateBupivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMagnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • jehan A Sayed, MD

    assistant professor in anesthesia and intensive care department,faculty of medicine,Assiut univeristy,egypt

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jehan A Sayed, MD

CONTACT

mohamed amir, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor (Anesthesiology and Critical Care)- College of Medicine

Study Record Dates

First Submitted

June 29, 2015

First Posted

July 1, 2015

Study Start

May 1, 2015

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

September 26, 2017

Record last verified: 2017-09

Locations